MC
AXSM icon

Moors & Cabot’s Axsome Therapeutics AXSM Stock Holding History

Moors & Cabot’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$394K Sell
2,330
-100
-4% -$17.3K 0.02% 612
2025
Q4 		$444K Buy
2,430
+50
+2% +$6.98K 0.02% 574
2025
Q3 		$289K Buy
2,380
+50
+2% +$5.63K 0.01% 685
2025
Q2 		$243K Buy
2,330
+100
+4% +$10.6K 0.01% 725
2025
Q1 		$260K Buy
+2,230
New +$254K 0.01% 689
2024
Q4 		– Sell
-2,230
Closed -$200K – 890
2024
Q3 		$200K Buy
+2,230
New +$195K 0.01% 804

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Moors & Cabot's AXSM Position: Q1 2026 in Review

Moors & Cabot reduced its Axsome Therapeutics (AXSM) stake by 4.1% in Q1 2026, selling an estimated $17.3K and leaving 2,330 shares worth $394K. The position accounts for 0.02% of the portfolio, ranked #612.

Moors & Cabot first reported a position in AXSM in Q3 2024 and has held it in 6 quarters since. The position peaked at $444K in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Moors & Cabot held 2,330 shares of Axsome Therapeutics worth $394K as of Q1 2026.
  • Moors & Cabot sold 100 Axsome Therapeutics shares in Q1 2026, an estimated $17.3K.
  • Axsome Therapeutics made up 0.02% of Moors & Cabot's portfolio in Q1 2026, its #612 holding.
  • Moors & Cabot first reported a position in Axsome Therapeutics in Q3 2024 and has held it in 6 quarters since.
  • Moors & Cabot's Axsome Therapeutics position peaked at $444K in Q4 2025.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Moors & Cabot's 13F filing for Q1 2026, filed 8 May 2026.